drugset / Trial / NCT01048580

Study of Perifosine + Capecitabine for Colon Cancer Patients

NCT01048580

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I study of Perifosine + Capecitabine for patients with advanced colon cancer.

Timeline

Start
2009-10
Primary completion
2011-05
Completion
2011-10

Publications

  • Results Journal of Oncology, 2010 ASCO Annual Meeting Abstracts. Vol. 28, No. 15_suppl (May 20Supplement), 2010:e14086

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Perifosine Small molecule 50 mg Oral

Indications